FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan

Prognosis of recurrent high-grade glioma (HGG) is poor, although bevacizumab has been documented in that context. This study aimed to determine the independent prognostic value of fluorodeoxyglucose (FDG)-PET on progression-free survival (PFS) and overall survival (OS) of recurrent HGG after combine...

詳細記述

保存先:
書誌詳細
主要な著者: Colavolpe, Cécile, Chinot, Olivier, Metellus, Philippe, Mancini, Julien, Barrie, Maryline, Bequet-Boucard, Céline, Tabouret, Emeline, Mundler, Olivier, Figarella-Branger, Dominique, Guedj, Eric
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2012
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337300/
https://ncbi.nlm.nih.gov/pubmed/22379188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos012
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料